I dont think that is possible at this stage, if there were any flaws in the submission the FDA would have flagged them at the mid-cycle review. Worst I can see happening is an extension to the approval date if they cannot agree on wording of the product description or naming, which I cannot foresee being an issue either.
Just my opinion and happy to be proven wrong by others more knowledgeable than me on this stuff.
Cheers
MTC
Ann: Letter to Shareholders - Notice of General Meeting, page-9
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.020(5.48%) |
Mkt cap ! $543.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 34.0¢ | $4.566M | 13.13M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 410003 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 346713 | 8 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |